Over the past three decades, dissolution testing has evolved into a powerful tool for characterizing the quality of oral pharmaceutical products. The dissolution test, at first exclusively a quality control test, is now emerging as a surrogate equivalence test for certain categories of orally administered pharmaceutical products.
Paracetamol is an active pharmaceutical ingredient, which exists in WHO Model List of Essential Medicines. Due to its highly soluble and highly permeable attribute it is classified to Class I according to Biopharmaceutics Classification System (BCS). It gives the opportunity to waive and to define the bioequivalence in vitro.
There is no approved comparator list in Mongolia. The innovator pharmaceutical product is usually the most logical comparator product for a multisource pharmaceutical product because its quality, safety and efficacy should have been well assessed and documented in premarketing studies and postmarketing monitoring schemes. There are registered 65 products in Mongolia, containing Paracetamol, and 6 of them are single component Paracetamol 500mg tablets in different pack sizes.
The comparator pharmaceutical product was selected according to criteria of a decision-tree format and Panadol was chosen as comparator according to the following criteria: Produced by GlaxoSmithKline, Dungarvan, Ireland, which is the International Conference on Harmonisation member country. Registered in Mongolia since 2009 and available in Mongolian market.
Objectives
Aim of this study is to define the interchangeability of locally produced generics: Paracetamol 500 mg tablets.
Materials and Methods
7 generic tablets containing Paracetamol in 500 mg were used as a material and Panadol tablets produced by GlaxoSmithKline as a comparator product.
In vitro bioequivalence testing was done according to the WHO Technical Report Series, No. 937, 2006, Annex 7: Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability.
Dissolution was tested in three media of pH 1.2, 4.5 and 6.8 in a volume of 900 ml, using a paddle apparatus at 75 rpm. Samples were taken after 15 minutes and the absorbance of filtered samples were measured at wavelength λ=257 nm.
Results 12 unit samples were tested in each of three media. Dissolution of 7 samples after 15 minutes are shown in Table 1 . According to the questionnaire, all manufacturers producing Paracetamol tablets formulated the dosage form in consideration of active pharmaceutical ingredient, excipients and machinery's specification. As criteria for choosing the formulation, manufacturers were used compendial monograph, stability study data and dissolution results.
Excipients such as mannitol, sorbitol, sodium bicarbonate, which fasten the drug absorption are not contained in Paracetamol formulations ( 
Discussion
According to the current regulation for registration of imported medicines bioequivalence study data is requested, while for registration of domestic medicines only dissolution data is requested. The study of interchangeability of multisource generic products still not requested as part of marketing authorization. With the economical growth the number of pharmaceutical manufacturers and number of imported and locally produced medicines are increasing. In mean time many sales representatives of foreign pharmaceutical producers promoting their products as innovators without proper scientific evidence, especially without strict bioequivalence study data. Mongolia adopts international standards and norms, mainly WHO guidelines and there is need to upgrade the registration rule with annex for establishment of interchangeability of multisource generic products.
According to the WHO guideline Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability and Kalantzi et al. suggested that paracetamol tablets may be biowaved from bioequivalence studies if the release of paracetamol from the tablets is greater than 85% in 15 minutes.
Conclusion
Paracetamol 500mg tablets produced by all 7 local manufacturers: LM1, LM2, LM3, LM4, LM5, LM6 and LM7 dissolved in more than 85% within 15 minutes in each of three media. Therefore the dissolution profile comparison with f2 test is unnecessary. Samples: LM1, LM2, LM3, LM4, LM5, LM6 and LM7 are bioequivalent and could be interchangeable with comparator pharmaceutical product. 
